Kalle Kurppa1, Aku Paavola2, Pekka Collin2, Harri Sievänen3, Kaija Laurila1, Heini Huhtala4, Päivi Saavalainen5, Markku Mäki1, Katri Kaukinen6. 1. Tampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Tampere, Finland. 2. Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital and School of Medicine, University of Tampere, Tampere, Finland. 3. UKK Institute, Tampere, Finland. 4. Tampere School of Health Sciences, University of Tampere and Tampere University Hospital, Tampere, Finland. 5. Research Program Unit, Immunobiology and Haartman Institute, Department of Medical Genetics, University of Helsinki, Helsinki, Finland. 6. Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital and School of Medicine, University of Tampere, Tampere, Finland; Seinäjoki Central Hospital, Seinäjoki, Finland. Electronic address: katri.kaukinen@uta.fi.
Abstract
BACKGROUND & AIMS: We investigated whether screen-detected and apparently asymptomatic adults with endomysial antibodies (EmA) benefit from a gluten-free diet (GFD). METHODS: We performed a prospective trial of 3031 individuals at risk for celiac disease based on screens for EmA. Of 148 seropositive individuals, 40 fulfilled inclusion criteria and were assigned randomly to groups placed on a GFD or gluten-containing diets. We evaluated ratios of small-bowel mucosal villous height:crypt depth, serology and laboratory test results, gastrointestinal symptom scores, physiologic well-being, perception of health by a visual analog scale, bone mineral density, and body composition at baseline and after 1 year. Thereafter, the group on the gluten-containing diet started a GFD and was evaluated a third time; subjects in the GFD group remained on this diet. RESULTS: After 1 year on the GFD, the mean mucosal villous height:crypt depth values increased (P < .001), levels of celiac-associated antibodies decreased (P < .003), and gastrointestinal symptoms improved to a greater extent than in patients on gluten-containing diets (P = .003). The GFD group also had reduced indigestion (P = .006), reflux (P = .05), and anxiety (P = .025), and better health, based on the visual analog scale (P = .017), than the gluten-containing diet group. Only social function scores improved more in the gluten-containing diet group than in the GFD group (P = .031). There were no differences between groups in laboratory test results, bone mineral density, or body composition. Most measured parameters improved when patients in the gluten-containing diet group were placed on GFDs. No subjects considered their experience to be negative and most expected to remain on GFDs. CONCLUSIONS: GFDs benefit asymptomatic EmA-positive patients. The results support active screening of patients at risk for celiac disease. Clinicaltrials.gov no: NCT01116505.
RCT Entities:
BACKGROUND & AIMS: We investigated whether screen-detected and apparently asymptomatic adults with endomysial antibodies (EmA) benefit from a gluten-free diet (GFD). METHODS: We performed a prospective trial of 3031 individuals at risk for celiac disease based on screens for EmA. Of 148 seropositive individuals, 40 fulfilled inclusion criteria and were assigned randomly to groups placed on a GFD or gluten-containing diets. We evaluated ratios of small-bowel mucosal villous height:crypt depth, serology and laboratory test results, gastrointestinal symptom scores, physiologic well-being, perception of health by a visual analog scale, bone mineral density, and body composition at baseline and after 1 year. Thereafter, the group on the gluten-containing diet started a GFD and was evaluated a third time; subjects in the GFD group remained on this diet. RESULTS: After 1 year on the GFD, the mean mucosal villous height:crypt depth values increased (P < .001), levels of celiac-associated antibodies decreased (P < .003), and gastrointestinal symptoms improved to a greater extent than in patients on gluten-containing diets (P = .003). The GFD group also had reduced indigestion (P = .006), reflux (P = .05), and anxiety (P = .025), and better health, based on the visual analog scale (P = .017), than the gluten-containing diet group. Only social function scores improved more in the gluten-containing diet group than in the GFD group (P = .031). There were no differences between groups in laboratory test results, bone mineral density, or body composition. Most measured parameters improved when patients in the gluten-containing diet group were placed on GFDs. No subjects considered their experience to be negative and most expected to remain on GFDs. CONCLUSIONS: GFDs benefit asymptomatic EmA-positive patients. The results support active screening of patients at risk for celiac disease. Clinicaltrials.gov no: NCT01116505.
Authors: M Barone; N Della Valle; R Rosania; A Facciorusso; A Trotta; F P Cantatore; S Falco; S Pignatiello; M T Viggiani; A Amoruso; R De Filippis; A Di Leo; R Francavilla Journal: Eur J Clin Nutr Date: 2015-07-15 Impact factor: 4.016
Authors: Jonas F Ludvigsson; Timothy R Card; Katri Kaukinen; Julio Bai; Fabiana Zingone; David S Sanders; Joseph A Murray Journal: United European Gastroenterol J Date: 2015-04 Impact factor: 4.623
Authors: Heba Iskandar; Darrell M Gray; Hongha Vu; Faiz Mirza; Mary Katherine Rude; Kara Regan; Adil Abdalla; Srinivas Gaddam; Sami Almaskeen; Michael Mello; Evelyn Marquez; Claire Meyer; Ahmed Bolkhir; Navya Kanuri; Gregory Sayuk; C Prakash Gyawali Journal: Postgrad Med J Date: 2017-01-09 Impact factor: 2.401
Authors: Jacalyn A See; Katri Kaukinen; Govind K Makharia; Peter R Gibson; Joseph A Murray Journal: Nat Rev Gastroenterol Hepatol Date: 2015-09-22 Impact factor: 46.802
Authors: Daniel A Leffler; Ciaran P Kelly; Peter H R Green; Richard N Fedorak; Anthony DiMarino; Wendy Perrow; Henrik Rasmussen; Chao Wang; Premysl Bercik; Natalie M Bachir; Joseph A Murray Journal: Gastroenterology Date: 2015-02-13 Impact factor: 22.682
Authors: Julio Valle; José Mario T Morgado; Juan Ruiz-Martín; Antonio Guardiola; Miriam Lopes-Nogueras; Almudena García-Vela; Beatriz Martín-Sacristán; Laura Sánchez-Muñoz Journal: United European Gastroenterol J Date: 2016-11-24 Impact factor: 4.623
Authors: Fabiana Zingone; Gillian L Swift; Timothy R Card; David S Sanders; Jonas F Ludvigsson; Julio C Bai Journal: United European Gastroenterol J Date: 2015-04 Impact factor: 4.623